Replies to post #47387 on Biotech Values

[DewDiligence]

>In this and other Dry AMD posts you seem to suggest that treating the Dry form (as opposed to preventing the progression to Wet) is not a significant opportunity.<

I think it is a significant opportunity, but it’s an opportunity with an especially high hurdle for safety and tolerability due to the slow-progressing nature of the disease.